Home WakeSpace Scholarship › Electronic Theses and Dissertations

THE NOVEL GEMCITABINE PHOSPHOLIPID CONJUGATE KPC34 HAS ACTIVITY AGAINST MULTIPLE MODELS OF RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA

Electronic Theses and Dissertations

Item Files

Item Details

abstract
Acute leukemias are cancers of the blood and bone marrow that affect thousands of Americans annually. These diseases can be myeloid or lymphoid in origin. Common components of therapy for both types of disease involve cytarabine and an anthracycline. After initially responding to treatment, most patients eventually relapse with disease that is resistant to conventional modalities. There is a pressing need for novel therapeutic agents to treat the acute leukemias, especially in the relapsed setting.
subject
Chemoresistance
Gemcitabine
Leukemia
Lipid conjugate
contributor
Alexander, Peter M. (author)
Pardee, Timothy S (committee chair)
Gmeiner, William H (committee member)
Kucera, Gregory L (committee member)
Marini, Frank C (committee member)
Wadas, Thaddeus J (committee member)
date
2015-06-23T08:35:52Z (accessioned)
2017-06-22T08:30:09Z (available)
2015 (issued)
degree
Cancer Biology (discipline)
embargo
2017-06-22 (terms)
identifier
http://hdl.handle.net/10339/57145 (uri)
language
en (iso)
publisher
Wake Forest University
title
THE NOVEL GEMCITABINE PHOSPHOLIPID CONJUGATE KPC34 HAS ACTIVITY AGAINST MULTIPLE MODELS OF RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA
type
Dissertation

Usage Statistics